Phase III trial data for Riavax shows extended survival in pancreatic cancer.- Samsung Pharm Co
It is known to extend survival in pancreatic cancer patients with high serum eotaxin levels when administered in combination with the current chemotherapy, Gemcitabine/Capecitabine. The RIAVAX Phase III clinical trial was conducted to investigate safety and efficacy when given in combination with Gemcitabine/Capecitabine in 148 patients with locally advanced and metastatic pancreatic cancer at 16 hospitals across Korea, including the Severance Hospital. The results of the clinical trial showed median overall survival (OS) of 11.3 months in the treatment group compared to 7.5 months in the control group, with statistically significant improvement (p=0.021). Another key endpoint which is time to tumor progression (TTP) also showed a statistical significance with 7.3 months in the treatment group compared with 4.5 months in the control group (p=0.021). No specific safety issues were reported. These results indicate that Riavax should be considered as one of the treatment options for patients with locally advanced and metastatic pancreatic cancer with high serum eotaxin levels. The study conducted in Korea was presented at the 2021 American Society of Clinical Oncology (ASCO) Annual meeting.